Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

22. Oktober 2025 07:30 ET | Quelle: Biogen Inc.

Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025

Dapirolizumab pegol (DZP) Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease activity/remission, flares, fatigue, joint pain and...
08. Januar 2025 15:35 ET | Quelle: Spherix Global Insights

New American College of Rheumatology Guidelines for Lupus Nephritis Recommend Triple Therapy, Highlighting a Shift in Current Treatment Practices, According to Spherix Global Insights

EXTON, PA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- At the 2024 American College of Rheumatology (ACR) Convergence, the organization unveiled updated guidelines for the screening, treatment, and management...
19. November 2024 01:00 ET | Quelle: Biogen Inc.

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity

Dapirolizumab pegol (DZP) met its primary endpoint, demonstrating statistically and clinically significant improvement across all organ systems as measured by BICLA, an endpoint measuring disease...